AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$BRSYF

BrainsWay Ltd (BRSYF) (Q3 2026) Earnings Call Highlights: Revenue Jumps 34% as Margins

BrainsWay Ltd reported a 34% revenue increase in Q3 2026, with gross margins expanding to 78%. CEO Hadar Levy expects continued growth and margin expansion into 2027, driven by a recurring-revenue model and strong demand for OCD coils. The company also highlighted international expansion and potential Alzheimer's research. Q3 operating cash flow was $6.2M, up from $1.4M a year earlier.

Original reporting
finance.yahoo.com
Published Nov 10, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BrainsWay Ltd (BRSYF) (Q3 2026) Earnings Call Highlights: Revenue Jumps 34% as Margins — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BRSYFBullishMed
01

Why it matters

The earnings beat and guidance raise suggest a short‑term rally, but execution risk remains in international rollout and new indications.

02

Market read

Earnings-driven catalyst for a micro‑cap medtech stock; potential upside for traders.

03

What to watch

Minority investments and international expansion could dilute near‑term earnings.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

BrainsWay Ltd (BRSYF) reported Q3 2026 results, highlighting revenue growth, margin improvement, and raised guidance.

Company-level read

Ticker impact

$BRSYFBullishHigh confidence
Context

Q3 2026 earnings call disclosed 34% revenue jump, higher gross margins and raised full-year guidance.

Expected impact

likely upward pressure as investors price in higher revenue and margin expansion

Evidence & confidence

Guidance lift and margin improvement are fresh primary disclosures that can move the stock in the near term.

Market effects

Sector

Strengthens outlook for the neurostimulation/medical device sector.

Regional

Positive for U.S. biotech and medtech investors.

Global

Limited to niche medical device market.

Counterpoint

What could challenge this read

Margin expansion may be temporary if volume growth slows; watch for cash burn on R&D.

Key entities

  • Company
    BrainsWay Ltd

    Medical device maker focused on deep TMS for OCD and depression.

Read at source← All news

Related articles

$DDOGHighAI 9/10

“Missing Forest-for-the-Trees”: Datadog Sinks 17% in a Week as Its Biggest AI Customer Cuts Back

Datadog (DDOG) stock fell 17% in a week after reporting 35% Q3 revenue growth to $1.2B but guiding Q4 revenue to $1.19-1.2B, roughly flat. The decline was driven by its largest AI customer reducing usage, though growth outside this customer is accelerating. Cloudflare (NET) reported strong Q3 results and a rising Q4 outlook, suggesting the slowdown may be isolated. Datadog trades at 60x forward earnings, below its usual multiple.

finance.yahoo.com
$NOVTHighAI 8/10

Novanta (NOVT) Q3 2026 Earnings Call Transcript

Novanta (NOVT) reported Q3 2026 revenue of $305M, up 23%, with organic growth of 10%. Adjusted EBITDA rose 38% to $80M, and adjusted EPS increased 21% to $1.05. The company acquired Riverpoint Medical, expanding its medical end markets to 53% of revenue. Customer bookings grew 29%, and backlog reached $543M. Operating cash flow tripled year-over-year to $156M. Novanta expects full-year 2027 gross margin expansion and strong earnings growth, driven by new products and acquisitions.

finance.yahoo.com
$AXONMed

Axon Sinks 27% in a Week to a New 52-Week Low. Is the Selling Overdone?

Axon shares dropped 27% in a week to a 52-week low after missing Q3 revenue estimates and lowering its 2026 outlook due to delayed federal Dedrone deployments. The company now expects $350M-$400M in free cash flow by 2026, down from $450M, and needs $450M in Q4 to meet targets. Competitors Motorola Solutions and Tyler Technologies reported strong demand. Analysts reduced 2027 EPS estimates to $9.55 from $10.51.

finance.yahoo.com
$INOHighAI 8/10

Inovio Q3 2026 slides: VOCERYQ approval amid wider loss

Inovio Pharmaceuticals reported a Q3 2026 net loss of $49.2M, wider than expected, despite FDA approval of VOCERYQ. Shares fell 3.97% to $1.45, then another 10.34% after hours. Operating expenses declined 7% YoY, but non-cash losses increased. Cash reserves total $48.4M, with a runway into late 2027. VOCERYQ targets recurrent respiratory papillomatosis, showing 50-100% surgery reduction in trials. The company plans a Q1 2027 launch and European filings by year-end.

investing.com